The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C

British Journal of Dermatology

Volumn 169, Issue 6, 2013, Pages 1295-1303

  Chiu, H Y ^a   Chen, C H ^a   Wu, M S ^a   Cheng, Y P ^a   Tsai, T F ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ASPARTATE AMINOTRANSFERASE; CYCLOSPORIN A; ENTECAVIR; ETANERCEPT; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 12; METHOTREXATE; RIBAVIRIN; USTEKINUMAB; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER SURGERY; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL STUDY; COLON CARCINOMA; DRUG SAFETY; ECHOGRAPHY; FAMILY HISTORY; FOLLOW UP; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; MIXED INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RECURRENT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; ULTRAVIOLET B RADIATION; VIRUS LOAD; VIRUS REACTIVATION; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; LIVER TUMOR; MIDDLE AGED; PSORIASIS; TUMOR RECURRENCE; VERY ELDERLY; VIRUS ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, HEPATOCELLULAR; DERMATOLOGIC AGENTS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PSORIASIS; RETROSPECTIVE STUDIES; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84888996879     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12461     Document Type: Article

References (62)

1. Reich K, Burden AD, Eaton JN, et al,. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol 2012; 166: 179-88.
2. Wang T-S, Tsai T-F,. Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept. Dermatol Sin 2013; 31: 11-18.
3. Marinos G, Naoumov NV, Rossol S, et al,. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 1995; 108: 1453-63.
4. Zylberberg H, Rimaniol AC, Pol S, et al,. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999; 30: 185-91.
5. Calabrese LH, Zein N, Vassilopoulos D,. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63 (Suppl. 2): ii18-24.
6. Kakumu S, Okumura A, Ishikawa T, et al,. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clin Exp Immunol 1997; 109: 458-63.
7. Calabrese LH, Zein NN, Vassilopoulos D,. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65: 983-9.
8. Cho YT, Chen CH, Chiu HY, et al,. Use of anti-tumor necrosis factor-alpha therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol 2012; 39: 269-73.
9. Menter A, Gottlieb A, Feldman SR, et al,. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-50.
10. Koskinas J, Tampaki M, Doumba PP, et al,. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in an HBsAg-negative anti-HBs-positive patient. Br J Dermatol 2013; 168: 679-80.
11. Navarro R, Vilarrasa E, Herranz P, et al,. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C. A retrospective, multicentre study in a clinical setting. Br J Dermatol 2013; 168: 609-16.
12. Chiu H-Y, Cheng Y-P, Tsai T-F,. T helper type 17 in psoriasis: from basic immunology to clinical practice. Dermatol Sin 2012; 30: 136-41.
13. Chen CH, Yang PM, Huang GT, et al,. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007; 106: 148-55.
14. Wu CY, Chen YJ, Ho HJ, et al,. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012; 308: 1906-14.
15. Lan JL, Chen YM, Hsieh TY, et al,. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2011; 70: 1719-25.
16. Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al,. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 90: 359-71.
17. Montiel PM, Solis JA, Chirinos JA, et al,. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008; 28: 718-20.
18. Nosotti L, Francesconi F, Izzi S, et al,. Safety of antitumour necrosis factor-alpha therapy in psoriatic patients with hepatitis B virus infection. Br J Dermatol 2010; 162: 1408-10.
19. Lalazar G, Rund D, Shouval D,. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699-712.
20. Torres HA, Davila M,. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012; 9: 156-66.
21. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
22. Hui C-K, Au W-Y, Lau GKK,. Preemptive therapy for hepatitis B patients undergoing chemotherapy. J Gastroenterol Hepatol 2004; 19: S124-7.
23. Lau GK, Yiu HH, Fong DY, et al,. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-9.
24. Chiu HY, Wang TS, Chang CY, et al,. The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis. J Eur Acad Dermatol Venereol 2012; 26: 991-8.
25. Tsai TF, Wang TS, Hung ST, et al,. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63: 40-6.
26. Abramson A, Menter A, Perrillo R,. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol 2012; 67: 1349-61.
27. Zein NN,. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315-22.
28. Brunasso AM, Puntoni M, Gulia A, et al,. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011; 50: 1700-11.
29. Abuchar A, Vitiello M, Kerdel FA,. Psoriasis treated with ustekinumab in a patient with hepatitis C. Int J Dermatol 2013; 52: 381-2.
30. Opel D, Economidi A, Chan D, et al,. Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab. J Drugs Dermatol 2012; 11: 1498-501.
31. Zeuzem S, Carreno V,. Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res 2001; 52: 181-8.
32. Cavanaugh VJ, Guidotti LG, Chisari FV,. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997; 71: 3236-43.
33. Xiong SQ, Lin BL, Gao X, et al,. IL-12 promotes HBV-specific central memory CD8 + T cell responses by PBMCs from chronic hepatitis B virus carriers. Int Immunopharmacol 2007; 7: 578-87.
34. Lohr HF, Pingel S, Bocher WO, et al,. Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B-restoration by exogenous interleukin-12. Clin Exp Immunol 2002; 130: 107-14.
35. Rossol S, Marinos G, Carucci P, et al,. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest 1997; 99: 3025-33.
36. Carreno V, Zeuzem S, Hopf U, et al,. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J Hepatol 2000; 32: 317-24.
37. Rigopoulou EI, Suri D, Chokshi S, et al,. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 2005; 42: 1028-36.
38. Cooper S, Erickson AL, Adams EJ, et al,. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439-49.
39. Lechner F, Wong DK, Dunbar PR, et al,. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 1499-512.
40. Lauer GM, Walker BD,. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
41. Shiina M, Kobayashi K, Satoh H, et al,. Ribavirin upregulates interleukin-12 receptor and induces T cell differentiation towards type 1 in chronic hepatitis C. J Gastroenterol Hepatol 2004; 19: 558-64.
42. Zhang JY, Zhang Z, Lin F, et al,. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 2010; 51: 81-91.
43. Xia L, Tian D, Huang W, et al,. Upregulation of IL-23 expression in patients with chronic hepatitis B is mediated by the HBx/ERK/NF-kappaB pathway. J Immunol 2012; 188: 753-64.
44. Ge J, Wang K, Meng QH, et al,. Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol 2010; 30: 60-7.
45. Matsui M, Moriya O, Belladonna ML, et al,. Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A*0201 transgenic mice. J Virol 2004; 78: 9093-104.
46. Wynn TA,. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4: 583-94.
47. Mentink-Kane MM, Cheever AW, Wilson MS, et al,. Accelerated and progressive and lethal liver fibrosis in mice that lack interleukin (IL)-10, IL-12p40, and IL-13Ralpha2. Gastroenterology 2011; 141: 2200-9.
48. Meng F, Wang K, Aoyama T, et al,. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012; 143: 765-76.e1-3.
49. Sun HQ, Zhang JY, Zhang H, et al,. Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis. J Viral Hepat 2012; 19: 396-403.
50. Bongartz T, Sutton AJ, Sweeting MJ, et al,. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
51. Colombo MP, Trinchieri G,. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-68.
52. Airoldi I, Di Carlo E, Cocco C, et al,. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci USA 2007; 104: 3996-4001.
53. Langowski JL, Zhang X, Wu L, et al,. IL-23 promotes tumour incidence and growth. Nature 2006; 442: 461-5.
54. Lo CH, Lee SC, Wu PY, et al,. Antitumor and antimetastatic activity of IL-23. J Immunol 2003; 171: 600-7.
55. Liu L, Shan B, Feng Y,. Antitumor effects and immunoregulation mechanisms of IL-23 gene in mouse mammary cancer mediated by retrovirus. Cell Immunol 2009; 258: 181-7.
56. Gordon KB, Papp KA, Langley RG, et al,. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 2012; 66: 742-51.
57. Kimball AB, Papp KA, Wasfi Y, et al,. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2012 Dec 20. doi: 10.1111/jdv.12046 [Epub ahead of print].
58. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al,. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010; 69: 1352-5.
59. Ghany MG, Strader DB, Thomas DL, et al,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
60. Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
61. Grulich AE, van Leeuwen MT, Falster MO, et al,. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67.
62. El-Serag HB,. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.